Dimensional Fund Advisors LP Has $4.23 Million Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Dimensional Fund Advisors LP decreased its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 18.8% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 88,746 shares of the company's stock after selling 20,557 shares during the period. Dimensional Fund Advisors LP owned about 0.06% of Ionis Pharmaceuticals worth $4,230,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Mather Group LLC. bought a new stake in shares of Ionis Pharmaceuticals in the first quarter worth $29,000. nVerses Capital LLC bought a new stake in Ionis Pharmaceuticals during the 2nd quarter worth about $29,000. Sunbelt Securities Inc. bought a new stake in Ionis Pharmaceuticals during the 1st quarter worth about $44,000. Advisors Asset Management Inc. boosted its stake in shares of Ionis Pharmaceuticals by 948.8% during the 1st quarter. Advisors Asset Management Inc. now owns 3,178 shares of the company's stock worth $138,000 after buying an additional 2,875 shares during the last quarter. Finally, Checchi Capital Advisers LLC bought a new position in shares of Ionis Pharmaceuticals in the 2nd quarter valued at about $202,000. Institutional investors own 93.86% of the company's stock.

Ionis Pharmaceuticals Stock Performance

Shares of IONS traded down $0.11 during midday trading on Thursday, reaching $37.95. 1,238,278 shares of the stock were exchanged, compared to its average volume of 1,332,421. The stock's 50 day simple moving average is $44.27 and its 200 day simple moving average is $43.46. The company has a market cap of $5.54 billion, a P/E ratio of -14.21 and a beta of 0.38. Ionis Pharmaceuticals, Inc. has a twelve month low of $35.95 and a twelve month high of $54.44. The company has a quick ratio of 7.51, a current ratio of 7.61 and a debt-to-equity ratio of 4.67.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.47. Ionis Pharmaceuticals had a negative net margin of 44.90% and a negative return on equity of 115.66%. The business had revenue of $225.00 million during the quarter, compared to analysts' expectations of $152.35 million. During the same quarter in the previous year, the company earned $0.60 EPS. The business's revenue was up 19.7% on a year-over-year basis. On average, sell-side analysts expect that Ionis Pharmaceuticals, Inc. will post -3.68 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Needham & Company LLC reissued a "buy" rating and set a $60.00 price target on shares of Ionis Pharmaceuticals in a research report on Friday, August 2nd. Leerink Partnrs raised Ionis Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, July 24th. BMO Capital Markets cut shares of Ionis Pharmaceuticals from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $67.00 to $60.00 in a research note on Friday, August 2nd. Stifel Nicolaus upped their price target on shares of Ionis Pharmaceuticals from $50.00 to $53.00 and gave the stock a "hold" rating in a research report on Thursday, June 27th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $70.00 price target on shares of Ionis Pharmaceuticals in a research note on Thursday, September 26th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Ionis Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $60.28.

Insider Activity at Ionis Pharmaceuticals

In related news, Director Joseph Klein III sold 12,000 shares of the firm's stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $50.00, for a total value of $600,000.00. Following the transaction, the director now owns 16,346 shares in the company, valued at approximately $817,300. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Joseph Klein III sold 12,000 shares of the company's stock in a transaction that occurred on Tuesday, July 16th. The shares were sold at an average price of $50.00, for a total transaction of $600,000.00. Following the completion of the sale, the director now owns 16,346 shares of the company's stock, valued at approximately $817,300. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Richard S. Geary sold 2,430 shares of the business's stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $48.00, for a total transaction of $116,640.00. Following the transaction, the executive vice president now owns 85,508 shares of the company's stock, valued at approximately $4,104,384. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 14,750 shares of company stock worth $732,371. Company insiders own 2.71% of the company's stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.